Literature DB >> 7318881

Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test.

P J Neuvonen, R A Tokola, M Kaste.   

Abstract

In a prospective study in nine patients the effects of phenytoin and of cimetidine (1000 mg/day) + phenytoin on the antipyrine test and serum phenytoin concentrations were studied. Serum phenytoin increased from the steady state level of 5.7 +1.3 mg/l to 9.1 +1.4 mg/l after three weeks on cimetidine (p less than 0.01), and fell to 5.8 +1.2 mg/l within two weeks after withdrawal of cimetidine. The protein binding of phenytoin was not changed by cimetidine. After use of phenytoin for 2-4 months, antipyrine clearance increased from 0.67 +0.06 ml/min/kg to 1.61 +0.22 ml/min/kg, and antipyrine half-live fell from 10.9 +1.3 h to 4.5 +0.6 h as compared to the values before phenytoin treatment (p less than 0.01). After three weeks combined use of cimetidine and phenytoin, antipyrine clearance was decreased to 1.01 +0.07 ml/min/kg and antipyrine half-life was prolonged to 6.1 +0.5 h, (p less than 0.01) compared to the values on phenytoin alone. The distribution volume of antipyrine was not affected by phenytoin nor by cimetidine + phenytoin. The half-life of cimetidine was 2.8 +0.3 h in the patients in the longterm phenytoin treatment. There was a significant positive correlation (p less than 0.001) between the increase in serum phenytoin concentration and the prolongation of antipyrine half-life caused by cimetidine. Thus, cimetidine increases serum phenytoin concentration, very probably by inhibiting its metabolism. Care should be taken in the concomitant use of cimetidine ad phenytoin, and the dose of phenytoin should be modified according to the clinical symptoms and serum phenytoin concentrations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7318881     DOI: 10.1007/bf00627923

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

3.  Micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid--a comparison between a gas chromatographic and a spectrophotometric method.

Authors:  A Berlin; S Agurell; O Borgå; L Lund; F Sjöqvist
Journal:  Scand J Clin Lab Invest       Date:  1972-05       Impact factor: 1.713

4.  Cimetidine potentiation of the hypoprothrombinemic effect of warfarin.

Authors:  B A Silver; W R Bell
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

5.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

6.  Antipyretic analgesics in patients on antiepileptic drug therapy.

Authors:  P J Neuvonen; R Lehtovaara; A Bardy; E Elomaa
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

7.  Factors affecting the bioavailability of phenytoin.

Authors:  P J Neuvonen; P J Pentikäinen; S M Elfving
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-02

8.  Cimetidine in the treatment of gastric ulcer: review and commentary.

Authors:  J W Freston
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

Review 9.  Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications.

Authors:  P J Neuvonen
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

10.  Displacement of phenytoin from plasma binding sites by salicylate.

Authors:  D G Fraser; T M Ludden; R P Evens; E W Sutherland
Journal:  Clin Pharmacol Ther       Date:  1980-02       Impact factor: 6.875

View more
  20 in total

1.  Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Authors:  U Klotz; I W Reimann
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

Review 2.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 3.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  Do nizatidine and cimetidine interact with ibuprofen?

Authors:  D R Forsyth; K S Jayasinghe; C J Roberts
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 6.  Mechanisms of unpredictable adverse drug reactions.

Authors:  M J Rieder
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

7.  Reduction of phenytoin clearance caused by cimetidine.

Authors:  G M Frigo; S Lecchini; M Caravaggi; G Gatti; M Tonini; L D'Angelo; E Perucca; A Crema
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 9.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

10.  Effects of chronic oral cimetidine on apparent liver blood flow and hepatic microsomal enzyme activity in man.

Authors:  T K Daneshmend; M D Ene; G Parker; C J Roberts
Journal:  Gut       Date:  1984-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.